Brokerages expect Endologix, Inc. (NASDAQ:ELGX) to post $45.20 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Endologix’s earnings. The highest sales estimate is $45.70 million and the lowest is $44.00 million. Endologix reported sales of $47.46 million during the same quarter last year, which would suggest a negative year over year growth rate of 4.8%. The business is expected to announce its next quarterly earnings report on Wednesday, February 28th.

According to Zacks, analysts expect that Endologix will report full-year sales of $45.20 million for the current financial year, with estimates ranging from $181.10 million to $182.90 million. For the next year, analysts expect that the company will post sales of $188.24 million per share, with estimates ranging from $185.67 million to $191.20 million. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that follow Endologix.

Several equities research analysts have commented on the company. Canaccord Genuity reissued a “hold” rating and issued a $5.00 target price on shares of Endologix in a report on Wednesday, September 27th. JPMorgan Chase & Co. downgraded Endologix from a “neutral” rating to an “underweight” rating in a report on Tuesday, January 2nd. ValuEngine downgraded Endologix from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Stifel Nicolaus decreased their price target on Endologix from $6.00 to $5.50 and set a “hold” rating for the company in a research note on Wednesday, November 8th. Finally, BidaskClub cut Endologix from a “buy” rating to a “hold” rating in a research note on Friday, December 15th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $5.41.

Endologix (NASDAQ:ELGX) traded down $0.03 during midday trading on Friday, hitting $4.59. The company had a trading volume of 565,964 shares, compared to its average volume of 603,148. The company has a quick ratio of 2.11, a current ratio of 2.90 and a debt-to-equity ratio of 2.61. Endologix has a one year low of $4.08 and a one year high of $7.66. The company has a market capitalization of $383.05, a price-to-earnings ratio of -4.94 and a beta of 0.72.

A number of institutional investors and hedge funds have recently modified their holdings of ELGX. Kopp Investment Advisors LLC increased its position in Endologix by 11.5% in the second quarter. Kopp Investment Advisors LLC now owns 21,950 shares of the medical instruments supplier’s stock worth $107,000 after buying an additional 2,270 shares in the last quarter. Verition Fund Management LLC bought a new stake in shares of Endologix in the 2nd quarter valued at approximately $111,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Endologix in the second quarter worth approximately $142,000. Valeo Financial Advisors LLC purchased a new position in Endologix during the 3rd quarter worth $163,000. Finally, UBS Asset Management Americas Inc. increased its holdings in Endologix by 128.1% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 34,898 shares of the medical instruments supplier’s stock worth $170,000 after purchasing an additional 19,600 shares during the period.

WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/01/13/zacks-brokerages-anticipate-endologix-inc-elgx-will-announce-quarterly-sales-of-45-20-million.html.

About Endologix

Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.

Get a free copy of the Zacks research report on Endologix (ELGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.